Rheumatoid Arthritis
From the Journals
Rheumatoid arthritis linked to increased Parkinson’s risk
“If patients with rheumatoid arthritis begin exhibiting motor symptoms such as muscle rigidity, tremors, or slowed movement, it is imperative that...
Conference Coverage
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
In about 5% of patients with seropositive RA, C-reactive protein levels were normal despite disease flares during a 5-year period. The findings...
Latest News
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
The announcement came after a pulmonary embolism occurred with the 12-mg twice-daily dose in one of the long-term open-label extension studies.
Feature
Researchers seek to understand post-COVID autoimmune disease risk
Three large studies link past SARS-CoV-2 infection to new-onset autoimmune disease, but it is not yet clear what drives this relationship.
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Conference Coverage
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs. anti–tumor necrosis factor (TNF) therapy for rheumatoid...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
From the Journals
DMARDs taper-to-discontinuation trial deemed inconclusive
For patients with RA in sustained remission taking half doses of conventional synthetic DMARDs, the risk of flare was similar to that from...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
From the Journals
Tofacitinib may have possible protective effect against ILD in RA
“Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk,” said study first...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...